Last update 07 Nov 2024

SBK-001

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
SBK-001, SBK001
Target
ACE2
Mechanism
ACE2 inhibitors(Angiotensin-converting enzyme 2 inhibitors)
Therapeutic Areas
Respiratory Diseases
Active Indication
Sputum excretion difficulty
Inactive Indication
Acute Lung Injury
Originator Organization
Chengdu Shibeikang Biomedical Technology Co Ltd
Active Organization
Chengdu Shibeikang Biomedical Technology Co Ltd
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with SBK-001
CTR20222019 / CompletedPhase 1
SBK001注射液多次给药在中国健康受试者中的 I 期耐受性、药代动力学研究。
[Translation] Phase I tolerability and pharmacokinetic study of multiple-dose SBK001 injection in healthy Chinese subjects.
CTR20220116 / CompletedPhase 1
SBK001注射液单次给药在中国健康受试者中的 I 期耐受性、药代动力学研究。
[Translation] Phase I tolerability and pharmacokinetic study of a single dose of SBK001 injection in healthy Chinese subjects.
CTR20244096 / Not yet recruitingPhase 2
一项评估SBK001注射液在痰液黏稠、排痰困难的下呼吸道疾病患者中有效性和安全性的多中心、随机、双盲、安慰剂和阳性药平行对照的Ⅱ期临床研究
[Translation] A multicenter, randomized, double-blind, placebo- and active drug-controlled Phase II clinical study to evaluate the efficacy and safety of SBK001 injection in patients with lower respiratory tract diseases with thick sputum and difficulty expectorating
100 Clinical Results associated with SBK-001
Login to view more data
100 Translational Medicine associated with SBK-001
Login to view more data
100 Patents (Medical) associated with SBK-001
Login to view more data
100 Deals associated with SBK-001
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Sputum excretion difficultyPhase 2
CN
Chengdu Shibeikang Biomedical Technology Co Ltd
04 Nov 2024
Acute Lung InjuryPhase 1
CN
Chengdu Shibeikang Biomedical Technology Co Ltd
16 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
CTR20222019 (Corporate Publications)
ManualManual
Phase 1
Acute Lung Injury
90
ypklxfcavj(gcpaedypmm) = 本品耐受性非常好，药代动力学呈现剂量依赖性 tkhpchpumh (jvjbgtvrpi )
Positive
26 Aug 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free